Innate Pharma S.A.
IPHYF
$1.45
-$0.31-17.61%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 98.36M | 99.04M | 102.20M | 97.86M | 97.04M |
| Total Receivables | 14.82M | 14.92M | 51.39M | 49.21M | 53.59M |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 3.22M | 3.25M | 6.29M | 6.03M | 3.63M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 3.17M | 3.19M | 3.73M | 3.57M | 3.43M |
| Total Current Assets | 119.57M | 120.39M | 163.60M | 156.66M | 157.70M |
|
|
|||||
| Total Current Assets | 119.57M | 120.39M | 163.60M | 156.66M | 157.70M |
| Net Property, Plant & Equipment | 6.16M | 6.20M | 6.99M | 6.69M | 7.93M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | 127.50K | 128.40K | 459.80K | 440.30K | 985.80K |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 25.38M | 25.55M | 21.72M | 20.79M | 11.61M |
| Total Assets | 162.32M | 163.44M | 203.60M | 194.95M | 217.30M |
|
|
|||||
| Total Accounts Payable | 9.38M | 9.44M | 9.46M | 9.06M | 10.77M |
| Total Accrued Expenses | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 9.57M | 9.63M | 9.88M | 9.46M | 5.82M |
| Total Finance Division Other Current Liabilities | 22.01M | 22.16M | 24.47M | 23.43M | 24.52M |
| Total Other Current Liabilities | 22.01M | 22.16M | 24.47M | 23.43M | 24.52M |
| Total Current Liabilities | 40.96M | 41.24M | 43.81M | 41.95M | 41.12M |
|
|
|||||
| Total Current Liabilities | 40.96M | 41.24M | 43.81M | 41.95M | 41.12M |
| Long-Term Debt | 28.30M | 28.49M | 33.83M | 32.40M | 38.00M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 175.70K | 176.90K | 386.90K | 370.40K | 566.60K |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 62.04M | 62.47M | 68.20M | 65.30M | 74.45M |
| Total Liabilities | 131.47M | 132.38M | 146.23M | 140.02M | 154.13M |
|
|
|||||
| Common Stock & APIC | 417.98M | 420.86M | 429.20M | 410.99M | 420.74M |
| Retained Earnings | -387.50M | -390.18M | -372.38M | -356.58M | -358.73M |
| Treasury Stock & Other | 380.40K | 383.00K | 547.10K | 523.90K | 1.16M |
| Total Common Equity | 30.85M | 31.07M | 57.37M | 54.93M | 63.17M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 30.85M | 31.07M | 57.37M | 54.93M | 63.17M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 30.85M | 31.07M | 57.37M | 54.93M | 63.17M |
|
|
|||||